肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

新型抗肿瘤药物临床应用指导原则(2022年版)

2022-12-30 中华人民共和国国家卫生健康委员会 卫健委官网 发表于上海

抗肿瘤药物

为进一步规范新型抗肿瘤药物临床应用，国家卫健委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2021年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2022

中文标题：

新型抗肿瘤药物临床应用指导原则(2022年版)

发布机构：

中华人民共和国国家卫生健康委员会

发布日期：

2022-12-30

简要介绍：

为进一步规范新型抗肿瘤药物临床应用，国家卫健委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2021年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2022年版）》。

相关资料下载：
[AttachmentFileName(sort=1, fileName=新型抗肿瘤药物临床应用指导原则(2022年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=dd9041c002899078, title=新型抗肿瘤药物临床应用指导原则(2022年版), enTitle=, guiderFrom=卫健委官网, authorId=0, author=, summary=为进一步规范新型抗肿瘤药物临床应用，国家卫健委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2021年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2022, cover=https://img.medsci.cn/20221109/1668021638994_4754896.webp, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Fri Dec 30 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #484848;"><span style="color: #484848; font-family: 仿宋_GB2312;">为进一步规范新型抗肿瘤药物临床应用，国家卫健委组织</span></span><span style="color: #484848;">国家卫生健康</span><span style="color: #484848;"><span style="color: #484848; font-family: 仿宋_GB2312;">委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（</span>20</span><span style="color: #484848;">21</span><span style="color: #484848;">年版）》进行修改完善，制定了</span><span style="color: #484848;">《新型抗肿瘤药物临床应用指导原则（</span><span style="color: #484848;">2</span><span style="color: #484848;">02</span><span style="color: #484848;">2</span><span style="color: #484848;">年版）》</span><span style="color: #484848;">。</span></p>, tagList=[TagDto(tagId=6223, tagName=抗肿瘤药物)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21043, categoryName=阜阳市肿瘤医院科研加速器, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3133, appHits=86, showAppHits=0, pcHits=593, showPcHits=3046, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Fri Jan 06 19:06:00 CST 2023, publishedTimeString=2022-12-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Dec 30 19:08:24 CST 2022, updatedBy=5472067, updatedName=梅斯病例, updatedTime=Fri Jan 05 15:47:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=新型抗肿瘤药物临床应用指导原则(2022年版).pdf)])
新型抗肿瘤药物临床应用指导原则(2022年版).pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2109173, encodeId=e95f21091e3da, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:40 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2109172, encodeId=8dec21091e2eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:24 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108378, encodeId=76af21083e819, content=新型<a href='/topic/show?id=6b68556562e' target=_blank style='color:#2F92EE;'>#抗肿瘤药物#</a><a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a><a href='/topic/show?id=222756406b7' target=_blank style='color:#2F92EE;'>#指导原则#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55656, encryptionId=6b68556562e, topicName=抗肿瘤药物), TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用), TopicDto(id=56406, encryptionId=222756406b7, topicName=指导原则)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Jan 01 10:34:34 CST 2023, time=2023-01-01, status=1, ipAttribution=上海)]
    2023-01-06 1252773em28暂无昵称 来自四川省

    很有帮助

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2109173, encodeId=e95f21091e3da, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:40 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2109172, encodeId=8dec21091e2eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:24 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108378, encodeId=76af21083e819, content=新型<a href='/topic/show?id=6b68556562e' target=_blank style='color:#2F92EE;'>#抗肿瘤药物#</a><a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a><a href='/topic/show?id=222756406b7' target=_blank style='color:#2F92EE;'>#指导原则#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55656, encryptionId=6b68556562e, topicName=抗肿瘤药物), TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用), TopicDto(id=56406, encryptionId=222756406b7, topicName=指导原则)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Jan 01 10:34:34 CST 2023, time=2023-01-01, status=1, ipAttribution=上海)]
    2023-01-06 1252773em28暂无昵称 来自四川省

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2109173, encodeId=e95f21091e3da, content=很有帮助, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:40 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2109172, encodeId=8dec21091e2eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6fd2543376, createdName=1252773em28暂无昵称, createdTime=Fri Jan 06 21:03:24 CST 2023, time=2023-01-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108378, encodeId=76af21083e819, content=新型<a href='/topic/show?id=6b68556562e' target=_blank style='color:#2F92EE;'>#抗肿瘤药物#</a><a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a><a href='/topic/show?id=222756406b7' target=_blank style='color:#2F92EE;'>#指导原则#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55656, encryptionId=6b68556562e, topicName=抗肿瘤药物), TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用), TopicDto(id=56406, encryptionId=222756406b7, topicName=指导原则)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Jan 01 10:34:34 CST 2023, time=2023-01-01, status=1, ipAttribution=上海)]
    2023-01-01 侠胆医心 来自上海

    新型#抗肿瘤药物##临床应用##指导原则#

    0

相关指南

《抗肿瘤生物类似药治疗药物监测药学专家共识（2020版）》解读

中国药理学会(Chinese Pharmacological Society) · 2020-05-30

肿瘤药物临床试验合同框架与关键条款专家共识

中国抗癌协会(Chinese Anti-cancer Association) · 2022-09-23

肿瘤临床试验的风险评估和质量管理共识（2021版）

中国抗癌协会中国肿瘤临床试验稽查协作组 · 2022-06-30

抗肿瘤药物说明书不良反应数据汇总指导原则

国家药品监督管理局药品审评中心（CDE） · 2022-04-21

2021年《新型抗肿瘤药物临床应用指导原则》解读与思考

武汉大学医院管理研究所 · 2022-03-15

抗肿瘤药物引起骨髓抑制中西医结合诊治专家共识

中国临床肿瘤学会(CSCO)中西医结合专家委员会 · 2021-11-15